Iovance Biotherapeutics

Historical price data

Iovance Biotherapeutics aims to be the global leader in developing and delivering TIL therapy for cancer patients. The company has achieved a landmark with the first FDA approval of a TIL therapy (Amtagvi/lifileucel) for advanced melanoma and is rapidly expanding into other solid tumors including non-small cell lung cancer (NSCLC), cervical cancer, and endometrial cancer. With a state-of-the-art manufacturing facility and multiple ongoing clinical trials, Iovance is positioned to transform cancer treatment through its personalized cell therapy platform.

Tumor-infiltrating lymphocyte (TIL) platform: a personalized, one-time cell therapy that expands a patient's own polyclonal T cells ex vivo to target diverse, patient-specific neoantigens in solid tumors.

29 drugs in pipeline, 1 in Phase 3

Total raised: $1.0B

Iovance is the first-mover in TIL therapy with an FDA-approved product. Main competitors include other TIL developers (Instil Bio, Turnstone), TCR-T companies (Adaptimmune, Immunocore), and personalized cancer vaccine makers. Iovance differentiates with its polyclonal TIL approach, proprietary manufacturing, and first-to-market approval.